Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients

Prophylaxis, Preemption and Drug Resistance in CMV Infection: Too Little, Too Much or Just Right?

(2011) J. A. Fishman   AMERICAN JOURNAL OF TRANSPLANTATION

High Incidence of Anticytomegalovirus Drug Resistance Among D+R− Kidney Transplant Recipients Receiving Preemptive Therapy

(2011) L. Couzi et al.   AMERICAN JOURNAL OF TRANSPLANTATION

GESITRA-SEIMC/REIPI recommendations for the management of cytomegalovirus infection in solid-organ transplant patients

(2011) Julian Torre-Cisneros et al.   ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA

Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis

(2011) A.A. Boudreault et al.   Transplant Infectious Disease

Therapeutic Effect of the Acquisition of Cytomegalovirus-Specific Immune Response During Preemptive Treatment

(2011) Omar J. BenMarzouk-Hidalgo et al.   TRANSPLANTATION

Unraveling the Biologic Basis of Late-Onset Cytomegalovirus Disease in High-Risk Organ Transplant Recipients

(2011) Nina Singh   TRANSPLANTATION

IMPACT Trial Results Should Not Change Current Standard of Care of 100 Days for Cytomegalovirus Prophylaxis

(2010) A. C. Kalil et al.   AMERICAN JOURNAL OF TRANSPLANTATION

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

(2010) A. Humar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients

(2010) Hsin-Yun Sun et al.   TRANSPLANT IMMUNOLOGY

Extended Valganciclovir Prophylaxis in D+/R− Kidney Transplant Recipients is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study

(2010) Atul Humar et al.   TRANSPLANTATION

International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation

(2010) Camille N. Kotton et al.   TRANSPLANTATION

Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients

(2009) D. Kumar et al.   AMERICAN JOURNAL OF TRANSPLANTATION

A new strategy of delayed long-term prophylaxis could prevent cytomegalovirus disease in (D+/R−) solid organ transplant recipients

(2009) R. San Juan et al.   CLINICAL TRANSPLANTATION

Prevention of Posttransplant Cytomegalovirus Disease and Related Outcomes with Valganciclovir: A Systematic Review

(2008) H-Y. Sun et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Improvement in Long-Term Renal Graft Survival due to CMV Prophylaxis with Oral Ganciclovir: Results of a Randomized Clinical Trial

(2008) V. Kliem et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Valganciclovir as Treatment for Cytomegalovirus Disease in Solid Organ Transplant Recipients

(2008) O. Len et al.   CLINICAL INFECTIOUS DISEASES

Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts

(2008) Nina Singh et al.   LIVER TRANSPLANTATION

Cytomegalovirus infection after liver transplantation: Current concepts and challenges

(2008) Raymund-Rabe Razonable   WORLD JOURNAL OF GASTROENTEROLOGY